Ipca Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
May 29, 2024 at 04:07 am
Share
Ipca Laboratories Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 20,330.1 million compared to INR 15,116.3 million a year ago. Revenue was INR 20,519.3 million compared to INR 15,480.2 million a year ago. Net income was INR 595.9 million compared to INR 765.2 million a year ago.
For the full year, sales was INR 77,050.4 million compared to INR 62,443.2 million a year ago. Revenue was INR 78,298.1 million compared to INR 63,699.4 million a year ago. Net income was INR 5,473.5 million compared to INR 4,713.2 million a year ago. Basic earnings per share from continuing operations was INR 25.82 compared to INR 18.58 a year ago. Diluted earnings per share from continuing operations was INR 21.57 compared to INR 18.58 a year ago.
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Pharma Nigeria Ltd., Trophic Wellness Pvt. Ltd.
IPCA LABORATORIES LIMITED 
